Theialife Sciences
1:45 PM - 2:00 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
Virtual Clinical stage (Phase 3 ready) Ophthalmology focused company with a lead molecule for pediatric myopia control. Post phase 2 clinical trials we have completed 12 years of real world clinical usage in Denmark and have treated over 1200 children. Our research was published in the British Journal of Ophthalmology in August 2022. Our IP remains intact for future 20 years. Dose and dosing is twice daily from diagnosis to late teen age years.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Dubai
Company HQ Country:
United Arab Emirates
Year Founded:
2015
Main Therapeutic Focus:
Ophthalmology
Lead Product in Development:
Novel Oral dosage form for pediatric control of high myopia
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
ONE
Speaker
